Suppr超能文献

成功治疗合并肝内胆管癌的结直肠癌肝转移:一例报告。

Successful treatment of colorectal liver metastasis harboring intrahepatic cholangiocarcinoma: A case report.

作者信息

Cheng Xiaofei, Zhao Feng, Chen Dong, Yang Piao, Zhong Weixiang, Xu Xiangming, Wang Weilin

机构信息

Department of Colorectal Surgery.

Department of Radiation Oncology.

出版信息

Medicine (Baltimore). 2018 Dec;97(51):e13751. doi: 10.1097/MD.0000000000013751.

Abstract

RATIONALE

Colorectal liver metastasis develops in 50% of patients diagnosed with colorectal cancer, whereas concurrent intrahepatic cholangiocarcinoma (ICC) and colorectal liver metastases is extremely rare.

PATIENT CONCERNS

A 72-year-old man was referred to our hospital complaining of abdominal discomfort, diarrhea, and weakness over the last month.

DIAGNOSES

Colorectal liver metastases concurrent intrahepatic cholangiocarcinoma (ICC).

INTERVENTIONS

The patient was treated with mFOLFOX6 (5-fluorouracil 2400 mg/m, leucovorin 400 mg/m, and oxaliplatin 85 mg/m) plus bevacizumab 5 mg/kg every 2 weeks for 2 months. However, chemotherapy was not effective for the liver S3 lesion in our case. The possibility of ICC was considered based on the multidisciplinary team (MDT) mode, together with an anomalous increase in cancer antigen 19-9 and a history of hepatolithiasis.

OUTCOMES

Simultaneous resection of the colon cancer and liver tumors was performed at 6 weeks after discontinuing bevacizumab. Colorectal liver metastases concurrent ICC was confirmed by postoperative pathology. The patient's disease-free survival time is currently >14 months.

LESSONS

This is the first case report of the diagnosis and timely treatment of colorectal liver metastases harboring ICC. These results suggest that multiple primary tumors should be considered as a differential diagnosis when imaging or laboratory test results are abnormal.

摘要

理论依据

50%被诊断为结直肠癌的患者会发生结直肠癌肝转移,而同时存在肝内胆管癌(ICC)和结直肠癌肝转移极为罕见。

患者情况

一名72岁男性因在过去一个月中出现腹部不适、腹泻和乏力而被转诊至我院。

诊断

结直肠癌肝转移合并肝内胆管癌(ICC)。

干预措施

患者接受了mFOLFOX6方案(氟尿嘧啶2400mg/m²、亚叶酸钙400mg/m²和奥沙利铂85mg/m²)联合贝伐单抗5mg/kg,每2周一次,共2个月的治疗。然而,在我们的病例中,化疗对肝脏S3段病变无效。基于多学科团队(MDT)模式,结合癌抗原19-9异常升高和肝内胆管结石病史,考虑了ICC的可能性。

结果

在停用贝伐单抗6周后,同时进行了结肠癌和肝脏肿瘤切除。术后病理证实为结直肠癌肝转移合并ICC。患者目前的无病生存时间>14个月。

经验教训

这是首例关于合并ICC的结直肠癌肝转移的诊断及及时治疗的病例报告。这些结果表明,当影像学或实验室检查结果异常时,应考虑多种原发性肿瘤作为鉴别诊断。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0560/6320161/095c9ec3564f/medi-97-e13751-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验